-logo-1200x675.png?v=20220303080937)
The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) major shareholder Jorey Chernett bought 60,985 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were acquired at an average cost of $3.29 per share, for a total transaction of $200,640.65. Following the purchase, the insider directly owned 10,176,929 shares in the company, valued at $33,482,096.41. This trade represents a 0.60% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Jorey Chernett also recently made the following trade(s):
- On Tuesday, March 17th, Jorey Chernett purchased 75,000 shares of Oncology Institute stock. The stock was acquired at an average cost of $3.42 per share, for a total transaction of $256,500.00.
- On Friday, March 13th, Jorey Chernett purchased 263,000 shares of Oncology Institute stock. The stock was acquired at an average price of $2.92 per share, with a total value of $767,960.00.
Oncology Institute Price Performance
Shares of TOI opened at $3.59 on Wednesday. The firm has a market cap of $353.18 million, a P/E ratio of -6.41 and a beta of 0.14. The Oncology Institute, Inc. has a 1 year low of $0.65 and a 1 year high of $4.88. The company has a 50 day simple moving average of $2.99 and a two-hundred day simple moving average of $3.39.
Oncology Institute (NASDAQ:TOI - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $141.96 million for the quarter, compared to the consensus estimate of $139.78 million. Oncology Institute had a negative net margin of 11.45% and a negative return on equity of 1,527.21%.
Analysts Set New Price Targets
Several research firms have commented on TOI. Needham & Company LLC reissued a "buy" rating and set a $5.00 price objective on shares of Oncology Institute in a report on Monday, March 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oncology Institute in a report on Wednesday, January 21st. B. Riley Financial boosted their target price on Oncology Institute from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Finally, BTIG Research reissued a "buy" rating and set a $7.00 price target on shares of Oncology Institute in a research note on Monday, March 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oncology Institute currently has a consensus rating of "Moderate Buy" and an average target price of $7.00.
View Our Latest Analysis on Oncology Institute
Institutional Investors Weigh In On Oncology Institute
A number of hedge funds have recently bought and sold shares of the business. Josh Arnold Investment Consultant LLC lifted its position in Oncology Institute by 1,104.3% during the fourth quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company's stock valued at $8,757,000 after purchasing an additional 2,255,559 shares during the last quarter. CenterBook Partners LP grew its stake in shares of Oncology Institute by 277.8% in the 3rd quarter. CenterBook Partners LP now owns 2,704,650 shares of the company's stock worth $9,439,000 after buying an additional 1,988,751 shares in the last quarter. Kanen Wealth Management LLC bought a new stake in shares of Oncology Institute in the 3rd quarter worth about $6,421,000. Marshall Wace LLP bought a new stake in shares of Oncology Institute in the 2nd quarter worth about $3,028,000. Finally, Geode Capital Management LLC raised its position in shares of Oncology Institute by 231.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company's stock valued at $2,623,000 after buying an additional 893,696 shares in the last quarter. Hedge funds and other institutional investors own 36.86% of the company's stock.
Oncology Institute Company Profile
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
